Oklo stock drops nearly 4% after co-founders shift 15 million OKLO shares into trusts
30 December 2025
2 mins read

Oklo stock drops nearly 4% after co-founders shift 15 million OKLO shares into trusts

NEW YORK, December 29, 2025, 8:43 PM ET — Market closed

  • Oklo fell 3.7% in regular trading and slipped about 1% in late after-hours quotes. 1
  • SEC filings showed CEO Jacob DeWitte and COO Caroline Cochran moved millions of shares into family trusts and grantor retained annuity trusts (GRATs) at $0. 2
  • Traders head into Tuesday watching Fed minutes and year-end liquidity conditions. 3

Oklo Inc. shares closed down 3.7% on Monday as investors digested insider ownership filings that disclosed large transfers of stock by the company’s co-founders. 1

The moves landed into thin year-end markets, when single-stock flows can have outsized impact and disclosure-driven headlines can set the tone. Oklo’s shares have swung sharply through December, after hitting triple-digit levels earlier in the month. 1

In separate Form 4 filings — documents insiders must submit to report trades and other ownership changes — CEO Jacob DeWitte reported gifting 7,851,901 Class A shares to the Jacob DeWitte Family Trust for no consideration, according to the filing. 2

The same filing also showed 7,583,085 shares moved for no consideration into the Caroline DeWitte Family Trust and 1,000,000 shares contributed to a grantor retained annuity trust, or GRAT. 2

Cochran’s Form 4 likewise described a transfer of 7,583,085 shares to the Caroline DeWitte Family Trust and trust contributions, with footnotes saying the insiders remained beneficial owners of shares held by the trusts. 4

GRATs are estate-planning trusts that can shift the future appreciation of assets to heirs while the grantor receives annuity payments. The filings collectively involved about 15.4 million shares, worth roughly $1.1 billion at Monday’s close. 2

Oklo ended the regular session at $74.09 after trading between $73.76 and $78.48, with about 8.4 million shares changing hands, according to StockAnalysis. The stock was quoted at $73.35 at 7:59 p.m. ET, down about 1% in after-hours trading. 1

The broader market drifted lower, with the SPDR S&P 500 ETF Trust down about 0.4% and the Invesco QQQ Trust off roughly 0.5% on the day.

Nuclear-linked names were mixed. NuScale Power fell about 2.4% and Centrus Energy slid nearly 2%, while Cameco was little changed.

Oklo describes itself as a fission technology and nuclear fuel recycling company that aims to deploy power plants to supply “clean, reliable, and affordable energy at scale,” according to its investor website. 5

In a Dec. 17 statement tied to work with Los Alamos National Laboratory, DeWitte said the company’s campaign was “part of a larger plan to turn America’s surplus fuel stockpiles into bridge fuel for advanced reactors.” 6

Before Tuesday’s session, investors will watch U.S. data including the S&P Case-Shiller home price index at 9:00 a.m. ET and the Chicago PMI survey at 9:45 a.m., followed by minutes from the Fed’s Dec. 9–10 meeting at 2:00 p.m. ET. 3

For Oklo, traders will focus on whether insider disclosures continue and whether the shares stabilize after a string of late-December declines; the stock is down about 11% from its Dec. 19 close. Earnings calendars tracked by Zacks currently point to the next report in late March 2026. 7

Stock Market Today

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

7 February 2026
Linde plc shares fell 2.5% to $448.24 Friday after reporting Q4 sales up 6% to $8.76 billion and adjusted EPS of $4.20. The company guided 2026 adjusted EPS to $17.40–$17.90, below analyst consensus. JPMorgan downgraded the stock, while Morgan Stanley and UBS raised price targets. Linde repurchased $1.4 billion in shares in Q4 and returned $7.4 billion to shareholders in 2025.
UiPath (PATH) stock ends flat after CEO share-sale filing as S&P MidCap 400 add nears
Previous Story

UiPath (PATH) stock ends flat after CEO share-sale filing as S&P MidCap 400 add nears

Marvell stock slips today as chips cool into year-end; MRVL traders eye Fed minutes and CES
Next Story

Marvell stock slips today as chips cool into year-end; MRVL traders eye Fed minutes and CES

Go toTop